Emergent BioSolutions Inc. — Director's Dealing 2021

Feb 26, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2021-02-24

Reporting Person: LINDAHL RICHARD S (EVP, Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-24	Common Stock	A	4011	—	Acquired	35790	Direct
2021-02-24	Common Stock	A	4012	—	Acquired	39802	Direct
2021-02-24	Common Stock	F	1010	$93.49	Disposed	38792	Direct
2021-02-26	Common Stock	F	819	$97.15	Disposed	37973	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-24	Employee Stock Options (Right to Buy)	$93.49	A	16043	Acquired	2028-02-23	Common Stock (16043.0)	Direct

Footnotes

F1: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

F2: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA margin calculated on a cumulative basis over the three-year period beginning January 1, 2021 and ending December 31, 2023, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%.

F3: Represents shares of common stock withheld to pay taxes.

F4: Vests in three equal installments beginning on the day prior to the anniversary date of the grant.